Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Dapiglutide Concentrations in Overweight/Obesity
NCT06758583Phase 1Completed
- Sponsor
- Zealand Pharma
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapiglutide in obesity and Overweight (2 arms), sponsored by Zealand Pharma. Primary endpoint: Pharmacokinetics of a single dose administration of 7.5 mg dapiglutide. Started Dec 2024; status: completed.
02
Drugs
dapiglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06758583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06758583.